Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14 ARF Tumor Suppressor Genes

18 Nov 2002

Abstract excerpt

The adenovirus mutant ONYX-015 is in phase III clinical trials as a novel antitumor therapy. Its apparent efficacy is thought to be due to its ability to replicate selectively in tumor cells defective in the signaling pathway for p53. Recent data have shown that p14(ARF), a positive regulator of p53, inhibits ONYX-015 replication in cells with a wild-type p53, a phenotype that characterizes normal cells. We,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cancer Research and Treatments
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12438574
DOI: 10.1128/jvi.76.24.12483-12490.2002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14 ARF Tumor Suppressor GenesPMID 12438574Read ↗

Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?Semantic proximity Read ↗

Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells.Semantic proximity Read ↗

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.Semantic proximity Read ↗

ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirusSemantic proximity Read ↗

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).Semantic proximity Read ↗

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.Semantic proximity Read ↗

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.Semantic proximity Read ↗

Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.Semantic proximity Read ↗

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.Semantic proximity Read ↗

Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.Semantic proximity Read ↗

Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53.Semantic proximity Read ↗

Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.